Kiniksa Pharmaceuticals International (KNSA) Retained Earnings (2017 - 2026)
Kiniksa Pharmaceuticals International (KNSA) posted Retained Earnings of -$439.5 million for Q1 2026, down 142.68% on a QoQ basis from $1.0 billion in Q4 2025, and down 145.3% year-over-year from $970.2 million in Q1 2025.
Kiniksa Pharmaceuticals International (KNSA) Retained Earnings (2017 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International's Retained Earnings history runs 10 years deep, the most recent figure standing at -$439.5 million for Q1 2026.
- Quarterly Retained Earnings fell 145.3% year-over-year to -$439.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$439.5 million (down 145.3% YoY) and the FY2025 annual result came in at $1.0 billion, up 7.3% from the prior year.
- Retained Earnings was -$439.5 million for Q1 2026 at Kiniksa Pharmaceuticals International, down from $1.0 billion in the prior quarter.
- Across five years, Retained Earnings topped out at $1.0 billion in Q4 2025 and bottomed at -$700.6 million in Q1 2022.
- A 5-year average of $10.2 million and a median of -$439.5 million in 2026 frame the typical range for Retained Earnings.
- Peak annual rise in Retained Earnings reached 15995266.67% in 2024, while the deepest fall reached 51225400.0% in 2024.
- Kiniksa Pharmaceuticals International's Retained Earnings stood at $888.1 million in 2022, then sank by 100.0% to $6000.0 in 2023, then jumped by 15995266.67% to $959.7 million in 2024, then gained by 7.3% to $1.0 billion in 2025, then slumped by 142.68% to -$439.5 million in 2026.
- Business Quant data shows KNSA's Retained Earnings at -$439.5 million in Q1 2026, $1.0 billion in Q4 2025, and -$476.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 37.04 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 28.20 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.11 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 4.54 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 8.83 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | -1.81 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 18.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 589.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -2.13 Bn |
| 10 | Kiniksa Pharmaceuticals International | 4.82 Bn | 4.36 Bn | 193.47 Mn | -439.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -439.55 Mn |
| Dec 31, 2025 | 1.03 Bn |
| Sep 30, 2025 | -476.34 Mn |
| Jun 30, 2025 | -494.77 Mn |
| Mar 31, 2025 | 970.24 Mn |
| Dec 31, 2024 | 959.72 Mn |
| Sep 30, 2024 | -512.26 Mn |
| Jun 30, 2024 | 934.77 Mn |
| Mar 31, 2024 | -495.65 Mn |
| Dec 31, 2023 | 6,000.00 |
| Sep 30, 2023 | -1,000.00 |
| Jun 30, 2023 | -489.33 Mn |
| Mar 31, 2023 | -504.30 Mn |
| Dec 31, 2022 | 888.12 Mn |
| Sep 30, 2022 | -496.50 Mn |
| Jun 30, 2022 | -90,000.00 |
| Mar 31, 2022 | -700.61 Mn |
| Dec 31, 2021 | -66,000.00 |
| Sep 30, 2021 | 853.14 Mn |
| Jun 30, 2021 | 844.26 Mn |